 |
市場調査レポート
商品コード
1441309
徐放性賦形剤の世界市場規模、シェア、成長分析、製品タイプ別、投与経路別、技術別-産業予測、2023～2030年Global Sustained Release Excipients Market Size, Share, Growth Analysis, By Product type(Gelatin, Polymers), By Route of Administration(Oral, Intramuscular), By Technology(Targeted Delivery, Microencapsulation) - Industry Forecast 2023-2030 |
||||||
| 徐放性賦形剤の世界市場規模、シェア、成長分析、製品タイプ別、投与経路別、技術別-産業予測、2023～2030年 |
|
出版日: 2024年02月22日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
徐放性賦形剤の世界市場規模は2022年に12億6,000万米ドルと評価され、2023年の13億7,000万米ドルから2031年には26億米ドルに成長し、予測期間（2024～2031年）のCAGRは8.4%で成長する展望です。
世界の徐放性賦形剤市場は着実な成長を遂げており、今後も拡大が見込まれます。徐放性賦形剤は、有効成分を長期間にわたって徐々に放出するように設計された製剤の重要な成分であり、これにより患者のコンプライアンスと治療成績が向上します。この市場は、慢性疾患の蔓延、革新的なドラッグデリバリーシステムに対する需要の増加、医薬品研究開発への投資の増加など、いくつかの要因によって牽引されています。さらに、人口の高齢化とそれに伴う長時間作用型薬剤の需要の急増が、市場の成長をさらに後押ししています。徐放性製剤には、ポリマー、脂質、ハイドロゲルなど、さまざまな賦形剤が利用されています。エチルセルロース、ヒドロキシプロピルメチルセルロース（HPMC）、ポリ（乳酸-コ-グリコール酸）（PLGA）などのポリマーは、生体適合性、放出制御特性、製剤化における汎用性により、特に顕著です。
目次
エグゼクティブサマリー
- 市場概要
- 繁栄と衰退
調査手法
- 情報調達
- セカンダリとプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資の分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
徐放性賦形剤の世界市場：製品タイプ別
- 市場概要
- ゼラチン
- ポリマー
- ミネラル
- 糖
- その他
徐放性賦形剤の世界市場：投与経路別
- 市場概要
- 経口
- 筋肉内
- 皮下
- 経皮
- 静脈内
- その他の投与経路
徐放性賦形剤の世界市場：技術別
- 市場概要
- 標的化導入
- マイクロカプセル化
- ウルスターテクニック
- その他の技術
徐放性賦形剤の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Allergan PLC（アイルランド）
- AstraZeneca（英国）
- GlaxoSmithKline PLC（英国）
- Mayne Pharma Group Limited（オーストラリア）
- Mylan NV（米国）
- Novartis AG（スイス）
- Pfizer Inc.（米国）
- Salix Pharmaceuticals（米国）
- Sun Pharmaceutical Industries Ltd（インド）
- Roche Holdings AG（スイス）
- Sanofi（フランス）
- Johnson & Johnson（米国）
- Eli Lilly and Company（米国）
- Merck & Co., Inc.（米国）
- Teva Pharmaceutical Industries Ltd（イスラエル）
- AbbVie Inc.（米国）
- Bristol-Myers Squibb（米国）
- Gilead Sciences, Inc.（米国）
- Bayer AG（ドイツ）
- Takeda Pharmaceutical Company Limited（日本）
Global Sustained Release Excipients Market size was valued at USD 1.26 billion in 2022 and is poised to grow from USD 1.37 billion in 2023 to USD 2.60 billion by 2031, growing at a CAGR of 8.4% in the forecast period (2024-2031).
The global sustained release excipients market was experiencing steady growth and is expected to continue expanding in the coming years. Sustained release excipients are crucial components in drug formulations designed to release active ingredients gradually over an extended period, thereby improving patient compliance and therapeutic outcomes. The market is driven by several factors, including the rising prevalence of chronic diseases, increasing demand for innovative drug delivery systems, and growing investment in pharmaceutical research and development. Additionally, the aging population and the subsequent surge in demand for long-acting medications further fuel market growth. Various excipients are utilized in sustained release formulations, including polymers, lipids, and hydrogels, among others. Polymers such as ethylcellulose, hydroxypropyl methylcellulose (HPMC), and poly (lactic-co-glycolic acid) (PLGA) are particularly prominent due to their biocompatibility, controlled release properties, and versatility in formulation.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sustained Release Excipients Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Sustained Release Excipients Market Segmental Analysis
Based on product type the market is segmented as Gelatin, Polymers, Minerals, Sugars, and Others. On the basis of route of administration the market is segmented as Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Other Routes of Administration. Based on technology, it is segregated into Targeted Delivery, Microencapsulation, Wurster Technique, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Sustained Release Excipients Market
One key market driver propelling the growth of the sustained release excipients market is the rising geriatric population worldwide. With aging populations, there is a higher incidence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions, necessitating long-term medication regimens. Sustained release formulations offer advantages in terms of improved patient compliance, reduced side effects, and enhanced therapeutic outcomes by maintaining consistent drug levels in the body over an extended period. Consequently, pharmaceutical manufacturers are increasingly incorporating sustained release excipients into their formulations to cater to the needs of the aging population, thereby driving market expansion.
Restraints in the Global Sustained Release Excipients Market
However, despite the promising growth prospects, the sustained release excipients market faces certain restraints that may hinder its growth trajectory. One notable challenge is the stringent regulatory requirements governing the approval and commercialization of sustained release formulations. Regulatory agencies impose rigorous standards for the safety, efficacy, and quality of pharmaceutical products, including those utilizing sustained release technologies. Meeting these regulatory guidelines demands substantial investments in research, development, and manufacturing capabilities, which can pose barriers to entry for smaller players and startups. Moreover, delays in regulatory approvals can prolong the time to market, impacting product launch timelines and revenue generation potential for companies operating in this space.
Market Trends of the Global Sustained Release Excipients Market
In terms of trends, there is a growing emphasis on the development of innovative sustained release excipients to address evolving market needs and enhance product performance. Manufacturers are investing in advanced formulation technologies and excipient materials to achieve optimized drug release profiles, improved bioavailability, and enhanced stability of pharmaceutical formulations. Additionally, there is increasing adoption of multifunctional excipients capable of providing additional functionalities such as taste masking, moisture protection, and modified release kinetics. Furthermore, strategic collaborations and partnerships between pharmaceutical companies and excipient suppliers are on the rise to leverage combined expertise and resources for product development and commercialization, thereby driving innovation and market growth in the sustained release excipients segment.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Sustained Release Excipients Market by Product type
- Market Overview
- Gelatin
- Polymers
- Minerals
- Sugars
- and Others
Global Sustained Release Excipients Market by Route of Administration
- Market Overview
- Oral
- Intramuscular
- Subcutaneous
- Transdermal
- Intravenous
- and Other Routes of Administration
Global Sustained Release Excipients Market by Technology
- Market Overview
- Targeted Delivery
- Microencapsulation
- Wurster Technique
- and Other Technologies
Global Sustained Release Excipients Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Allergan PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mayne Pharma Group Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan NV (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Salix Pharmaceuticals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holdings AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
